Have statins met our expectations? A comparison of expected health gains from statins with epidemiological trends in Austria

Journal of Public Health (Germany)

Volumn 20, Issue 1, 2012, Pages 31-39

  Zechmeister, Ingrid ^a   Ara, Roberta ^b   Ward, Sue ^b   Stollenwerk, Björn ^c,d  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Cardiovascular diseases; Cohort model; Population health; Secondary prevention; Statins

Indexed keywords

STATIN;

ARTICLE; AUSTRIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 84863465378     PISSN: 09431853     EISSN: 16132238     Source Type: Journal    
DOI: 10.1007/s10389-011-0440-4     Document Type: Article

References (18)

1. Allender S, Scarbourough P, Petov V, Rayner M, Leal J, Luengo- Fernandez R, Gray A (2008) European Cardiovascular Disease Statistics 2008. British Heart Foundation, London
2. Azeem M, Aylin P, Williams S, Bottle A, Jarman B (2004) Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 329:654
3. Bennett K, Kabir Z, Unal B, Shelley E, Critchley J, Perry I, Feely J, Capewell S (2006) Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health 60:322-327
4. Folino-Gallo P, Walley T, Melander A, deJoncheere K, van Ganse E, Schwabe U (2005) Can we assess the impact of medicine utilisation on population health? The example of statins utilisation and coronary heart diseasemortality. In: Tellnes G (ed) Urbanization and health. University Press, Oslo
5. Ford ES, Ajani UA, Croft JB, Critchley J, Labarthe DR, Kottke TE, Giles WH, Capewell S (2007) Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 356:2388-2398 (Pubitemid 46883773)
6. Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, Schreiber W, Unger G, Glogar HD, Kaff A, Laggner AN, Maurer G, Mlczoch J, Slany J, Weber HS, Huber K, Vienna STEMI Registry Group (2006) Implementation of guidelines improves the standard of care: the Viennese registry of reperfusion strategies in ST-elevation myocardial infarction. Circulation 113:2398-2405 (Pubitemid 43948047)
7. Klimont J, Kytir J, Leitner B (2007) Österreichische Gesundheitsbefragung 2006/2007. Hauptergebnisse und methodische Dokumentation. Statistik Austria, Wien
8. Mühlberger N, Barbieri V, Pachinger O (2004) Koronarangiographie und PCI in Österreich im Jahr 2003. J für Kardiologie 11:403-411
9. Mühlberger N, Barbieri V, Pachinger O (2006) Koronarangiographie und PCI in Österreich im Jahr 2004 (mit Audit 2005 und 2005). J für Kardiologie 13:1-12 (Pubitemid 43232253)
10. Statistik Austria (2008) Todesursachenstatistik. Statistik Austria, Wien
11. Stollenwerk B, Gerber A, Lauterbach KW, Siebert U (2009) The German coronary artery disease risk screening model: development, valdiation and application of a decision analytic model for coronary artery disease prevention with statins. Med Decis Making 29:619-633
12. Unal B, Capewell S, Critchley J (2006) Coronary heart disease policy models: a systematic review. BMC Public Health 6:213-223
13. Unal B, Critchley J, Capewell S (2004) Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 109:1101-1107 (Pubitemid 38332613)
14. Unal B, Critchley J, Capewell S (2005) Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 331:614
15. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Yeo W, Payne N (2007) A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess (Winch Eng) 11:1-184
16. Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular diseases Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104:2746-2753 (Pubitemid 33108145)
17. Zechmeister I, Stollenwerk B, Ara R, Ward S (2008) Statins for the Secondary Prevention of Cardiovascular Disease. An Analysis of Population Health Gains and Cost-Utility in Austria. Ludwig Boltzmann Institut für Health Technology Assessment, Wien
18. Zechmeister I,Wild C (2006) Einsatz von Statinen zur Sekundä rprävention kardio-vaskulärer Erkrankungen. Ein systematischer Review gesundheitsökonomischer Analysen. Institut für Technikfolgenabschätzung, Wien